SequelSEC

Processa Pharmaceuticals, Inc. PCSA

Pharmaceutical Preparations · CIK 0001533743 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2023-09-30
Operating income
-$22.06M
Fiscal year ended 2023-09-30
Free cash flow
Unavailable
Fiscal year ended 2023-09-30

Processa Pharmaceuticals, Inc. (PCSA) reported revenue of $0 and net income of -$21.73M for the fiscal year ended 2023-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Processa Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Processa Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-09-30
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$22.06M
Net income-$21.73M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$7.15M
Selling & marketingUnavailable

Balance

Processa Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-09-30
Cash & equivalents$6.86M
Total assets$8.08M
Current assets$7.91M
Total liabilities$914.85K
Current liabilities$826.07K
Total equity incl. NCI$7.17M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$346.30K

Cash flow

Processa Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-09-30
Operating cash flow-$8.44M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$6.25M
Net change in cash-$2.19M
Stock-based compensation$3.58M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Processa Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-09-30
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio9.57x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PCSA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-18View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.